Page last updated: 2024-09-03

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and optimark

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with optimark in 1 studies

Compound Research Comparison

Studies
(gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate)
Trials
(gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate)
Recent Studies (post-2010)
(gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate)
Studies
(optimark)
Trials
(optimark)
Recent Studies (post-2010) (optimark)
63831243741226

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA1

Other Studies

1 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and optimark

ArticleYear
Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
    Radiology, 2010, Volume: 256, Issue:3

    Topics: Adult; Cell Proliferation; Collagen; Contrast Media; Dose-Response Relationship, Drug; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hyaluronic Acid; Linear Models; Magnetic Resonance Imaging; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds

2010